Earth Science Tech Announces The Formation Of The Advisory Board And Welcomes World Renowned Scientist Wei R Chen PhD As The First Advisory Board Member

LAS VEGAS, NV--(Marketwired - May 12, 2014) - Earth Science Tech, Inc. (OTCQB: UNOV) (“EST” or “the Company”), a specialty biotechnology company focused on nutraceuticals and bioceuticals, today announced its new advisory board and welcomes the addition of World Renowned Scientist Wei R Chen PhD as its first board advisor. The board will provide tactical and strategic leadership on the company’s growth and purpose in the viable industry landscape, and offer guidance on the latest advances influencing science and technology within the nutraceutical and bioceutical markets.

“The new advisory board will represent a variety of diverse backgrounds, including international professionals and leaders from a variety of fields. EST and its shareholders at large will look to benefit from the new ideas and fresh energy the advisory board will bring to our growing business and the expansion of EST. We look forward to the advice and direction these distinguished leaders will provide our company,” says EST CEO, Harvey Katz PhD.

Below is a short bio on Wei R. Chen, PhD. To view the full bio visit http://www.earthsciencetech.com/about/.

Wei R. Chen PhD is currently a Professor of Biomedical Engineering in the Department of Engineering and Physics and Assistant Dean of the College of Mathematics and Science at the University of Central Oklahoma. He is also the Founder and Director of the Center for Interdisciplinary Biomedical Education and Research at the University of Central Oklahoma.

Dr. Chen is a co-inventor of laser immunotherapy, a novel method for treatment of metastatic cancers, using a combination of phototherapy and immunotherapy. He is also a co-inventor of glycated chitosan, a novel immunological stimulant, for cancer treatment and is conducting laser immunotherapy clinical trials for late-stage melanoma and breast cancer patients in the United States, the Bahamas, and Peru. The clinical results using laser immunotherapy in the treatment of late-stage, metastatic, and often no-option, cancer patients are extremely promising. Dr. Chen is also the inventor of an immunologically modified carbon nanotubes, which can be used for drug delivery, cancer diagnosis, and synergistic phototherapy and immunotherapy for metastatic cancers.

Dr. Chen has been awarded seven US patents and several international patents, with several patents pending. In 2006, he established and has since chaired the SPIE (International Society for Optics and Photonics) international conference “Biophotonics and Immune Responses”. He is the Editor-in-Chief for the Journal of X-Ray Science and Technology and serves on the editorial board of several other journals. Dr. Chen has received numerous international, national, and regional awards. He was elected a SPIE (International Society of Optics and Photonics) Fellow in 2007. In 2008, Dr. Chen was named the US Professor of the Year. In 2011, he received the Oklahoma Medal for Excellence in Teaching. Dr. Chen is also a recipient of the 2011-2012 United States Fulbright Lecturing/Research Award. In 2012, he received the SPIE Educator Award and served in SPIE Education Committee from 2009 to 2011 and SPIE Fellows Committee from 2010 to 2013.

ABOUT: EST is a unique biotechnology company focused on cutting edge nutraceuticals and bioceuticals designed to excel in industries such as health, wellness, nutrition, supplement, cosmetic and alternative medicine to improve the quality of life for consumers worldwide. EST is dedicated in providing natural alternatives to prescription medications that help improve common disorders and illnesses. EST is focused on delivering nutritional and dietary supplements that help with treating symptoms such as: chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, aging and overall wellness. This may include products such as vitamins, minerals, herbs, botanicals, personal care products, homeopathics, functional foods, and other products. These products will be in various formulations and delivery forms including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

FORWARD LOOKING DISCLAIMER: This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts’ expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company’s future stock price, its revenues or results of operations.